

CD40 Ligand - Pipeline Review, H2 2019

<https://marketpublishers.com/r/CDF127C70095EN.html>

Date: December 2019

Pages: 74

Price: US\$ 3,500.00 (Single User License)

ID: CDF127C70095EN

Abstracts

CD40 Ligand - Pipeline Review, H2 2019

SUMMARY

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 7 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System and Genetic Disorders which include indications Autoimmune Disorders, Graft Versus Host Disease (GVHD), Amyotrophic Lateral Sclerosis, Breast Cancer, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Auto Inflammatory Disease, Bladder Cancer, Colon Cancer, Hepatocellular Carcinoma, Inflammation, Kidney Transplant Rejection, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer,

Pancreatic Islet Transplant Rejection, Sicca Syndrome (Sjogren), Solid Tumor and Transplant Rejection.

The latest report CD40 Ligand - Pipeline Review, H2 2019, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily

Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects

The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis

Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development

Anelixis Therapeutics LLC

Bristol-Myers Squibb Co

eTheRNA Immunotherapies NV

Memgen LLC

NapaJen Pharma Inc

Sanofi

Shattuck Labs Inc

TILT Biotherapeutics Ltd

Tonix Pharmaceuticals Holding Corp

UCB SA

Viela Bio Inc

XL-protein GmbH

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles

AT-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapirolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate CD40LG for Genetic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISF-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

letolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NJA-730 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-441344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-115154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-172154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TILT-234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-1500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIB-4920 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant

Products

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Discontinued Products

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones

Featured News & Press Releases

Dec 11, 2019: Viela Bio announces initiation of phase 2b trial of VIB4920 in Sjogren's Syndrome

Nov 08, 2019: UCB Presents new data on investigational molecule Dapirolizumab Pegol at the 2019 American College of Rheumatology and the Association of Rheumatology Professionals (ACR/ARP) Annual Meeting

Aug 21, 2019: Tonix Pharmaceuticals and Massachusetts General Hospital enter into research collaboration to develop Tonix's third generation anti-CD154 monoclonal antibody, TNX-1500, for the treatment and prevention of organ transplant rejection

Jun 01, 2019: Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL

Mar 04, 2019: eTheRNA immunotherapies completes patient enrolment for Phase 1b study in adjuvant melanoma

Nov 28, 2018: Augie's Quest reports first subject successfully enrolled in AT-1501 phase 1 study, a first-of-its-kind, promising treatment for ALS

Nov 15, 2018: NapaJen Pharma announces first patient dosed in phase 1 first-in-human clinical trial of novel RNA interference (RNAi) therapeutic

Oct 23, 2018: UCB and Biogen announce topline results from a phase 2b study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

Oct 19, 2018: Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920 at the 2018 ACR/ARHP Annual Meeting

Oct 08, 2018: eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies

May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies

Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)

Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with

Checkpoint Inhibitors in a Model of Metastatic Melanoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Anelixis Therapeutics LLC, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by eTheRNA Immunotherapies NV, H2 2019
Pipeline by Memgen LLC, H2 2019
Pipeline by NapaJen Pharma Inc, H2 2019
Pipeline by Sanofi, H2 2019
Pipeline by Shattuck Labs Inc, H2 2019
Pipeline by TILT Biotherapeutics Ltd, H2 2019
Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019
Pipeline by UCB SA, H2 2019
Pipeline by Viela Bio Inc, H2 2019
Pipeline by XL-protein GmbH, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Anelixis Therapeutics LLC
Bristol-Myers Squibb Co
eTheRNA Immunotherapies NV
Memgen LLC
NapaJen Pharma Inc
Sanofi
Shattuck Labs Inc
TILT Biotherapeutics Ltd
Tonix Pharmaceuticals Holding Corp
UCB SA
Viela Bio Inc
XL-protein GmbH

I would like to order

Product name: CD40 Ligand - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/CDF127C70095EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDF127C70095EN.html>